

Almirall and Evotec enter into a multi-target alliance in Medical Dermatology

- The multi-target research and development partnership will focus on severe skin diseases, including immune-mediated inflammatory conditions such as atopic dermatitis and non-melanoma skin cancer such as basal cell carcinoma
- The collaboration leverages Evotec's data-driven EVOiR&D platform for integrated discovery and development of first-in-class therapies and Almirall's expertise in Medical Dermatology

BARCELONA, Spain, and HAMBURG, Germany. May 19, 2022 – **Almirall, S.A. (ALM)**, a global biopharmaceutical company focused on skin health, and **Evotec SE** (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO), a globally operating life science company, announced today a **multi-target alliance in Medical Dermatology**. The companies aim to discover and develop novel therapeutics for severe skin diseases, including immune-mediated inflammatory conditions such as atopic dermatitis and non-melanoma skin cancer such as basal cell carcinoma.

The alliance will leverage Evotec's fully integrated multimodality platform and combine it with Almirall's leading expertise in Medical Dermatology. Both partners will contribute drug targets in the research process. Leveraging the company's end-to-end integrated, AI/ML-driven **EVOiR&D** platform, Evotec will be responsible for drug discovery and pre-clinical development. Almirall will lead the clinical development and marketing.

Under the agreement, Evotec receives an undisclosed upfront payment, research payments, as well as success-based milestones of potentially up to € 230 m per programme and royalties on net sales in the high single-digit percentage range.

Dr. Karl Ziegelbauer, Chief Scientific Officer of Almirall, stated: *"We are very excited about the strategic alliance with Evotec and believe that combining Almirall's experience and know-how in Medical Dermatology with Evotec's integrated drug discovery and preclinical development small molecule platform will enable us to deliver novel solutions for patients suffering from auto-immune skin diseases or common forms of skin cancer."*

Dr. Werner Lanthaler, Chief Executive Officer of Evotec, commented: *"We are very happy to enter this collaboration with Almirall, one of the leaders in the field of Medical Dermatology. The collaboration has the potential to deliver superior first-in-class therapeutic options for many patients suffering from severe skin diseases such as atopic dermatitis or basal cell carcinoma. We are looking forward to leveraging the complementary expertise of Evotec and Almirall in order to develop promising new drug candidates."*

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient's needs through science to improve their lives. Our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 79-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, with about 1,800 employees. Total revenues in 2021 were 836.5 million euros.

For more information, please visit almirall.com

About Evotec SE

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g., neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,200 highly qualified people. The Company's 15 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence.

For additional information, please go to <http://www.evotec.com/> and follow us on Twitter [@Evotec](https://twitter.com/Evotec) and [LinkedIn](https://www.linkedin.com/company/evotec).

Media contact Almirall:

Tinkle
Laura Blázquez
lblazquez@tinkle.es
Phone: (+34) 600 430 581

Investors' Relations contact

Almirall
Pablo Divasson del Fraile
pablo.divasson@almirall
Phone: (+34) 93 291 3087

Corporate Communications contact:

Almirall
Ester Riu
ester.riu@almirall.com
Phone: (+34) 671 580 438

Media contacts Evotec:

Gabriele Hansen
SVP Head of Global Corporate
Communications & Marketing
Gabriele.Hansen@evotec.com
Phone: +49.(0)40.56081-255

Evotec IR contact:

Volker Braun
SVP Head of Global
Investor Relations & ESG
Volker.Braun@evotec.com
Phone: +49 (0) 40 56081 775

Hinnerk Rohwedder
Senior Specialist Corporate
Communications
Hinnerk.Rohwedder@evotec.com
Phone: +49 (0) 151 4070 4843

Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.

